AgeX Therapeutics Inc represents innovation, scientific excellence, and a patient-centered approach in the field of regenerative medicine. The company is committed to developing and commercializing breakthrough technologies that target the underlying causes of aging-related diseases. AgeX Therapeutics Inc believes in the power of stem cells and focuses on advancing the potential of induced pluripotent stem cells (iPSCs) to rejuvenate and repair damaged tissues. With a strong emphasis on research and collaboration, AgeX Therapeutics Inc aims to transform the way age-related conditions are treated, ultimately improving the quality of life for patients.

AgeX Therapeutics Inc is primarily present in the United States.

AgeX Therapeutics Inc. has achieved several significant milestones since its inception. Firstly, the company successfully developed its proprietary PureStem® and UniverCyte™ technology platforms, which serve as a foundation for the development of regenerative medicine products. They also established the AgeX Bioengineering Division to advance the life extension and rejuvenation technology. Additionally, AgeX formed a subsidiary, LifeBio, focused on using artificial intelligence and big data analytics to extend human health span. Furthermore, AgeX Therapeutics made strategic collaborations and partnerships, including a licensing agreement with Lineage Cell Therapeutics for the development and commercialization of OpRegen®, a retinal pigment epithelium transplant therapy. These achievements highlight the company's dedication to advancing regenerative medicine and positioning itself as a leader in the field.

AgeX Therapeutics Inc is a life sciences company focused on developing and commercializing innovative technologies to reverse the effects of aging. Founded in 2017, AgeX is a subsidiary of BioTime Inc., with headquarters in Alameda, California. The company is dedicated to leveraging breakthroughs in the field of regenerative medicine to address the challenges posed by age-related diseases. AgeX Therapeutics Inc's research and development efforts primarily revolve around the identification and utilization of pluripotent stem cells, tissue engineering, and bioengineering technologies. By utilizing these advanced approaches, AgeX aims to improve human health and extend the healthy lifespan.

Some of the main competitors of AgeX Therapeutics Inc in the market are companies like BioTime Inc and Lineage Cell Therapeutics Inc.

AgeX Therapeutics Inc is primarily active in the biotechnology industry.

The business model of AgeX Therapeutics Inc is focused on the development and commercialization of innovative therapies for the aging process and age-related diseases. By leveraging their proprietary technologies and research expertise, AgeX aims to address the underlying causes of aging and enhance human healthspan. The company is dedicated to identifying and targeting specific biological mechanisms that contribute to age-related decline, with the potential to extend healthy lifespans. AgeX Therapeutics Inc combines regenerative medicine, cell therapy, and genetic engineering to explore groundbreaking solutions for age-related diseases such as osteoarthritis. Their comprehensive approach positions AgeX as a leading player in the field of longevity and rejuvenation research.

Az KGV a AgeX Therapeutics esetében jelenleg nem számítható ki.

A AgeX Therapeutics számára az aktuális KUV nem számítható ki.

Az AlleAktien Minőségi Score AgeX Therapeutics esetében 1/10.

A AgeX Therapeutics esetében jelenleg nem számítható ki az árbevétel.

A nyereséget jelenleg nem lehet kiszámítani a AgeX Therapeutics számára.

AgeX Therapeutics Inc is a US-based company specializing in the development of therapeutic agents for rejuvenation and regeneration of tissues and organs. The company was founded in 2017 and is headquartered in Alameda, California. The business model of AgeX Therapeutics is based on the discovery and development of new technologies and therapeutic approaches to improve the health and quality of life of people. The company focuses on the research of stem cells and their ability to regenerate tissues and organs. AgeX Therapeutics is divided into several business segments, each focusing on specific therapeutic approaches. One of these business segments is the production of cell lines that have undergone paramyxovirus-based de-differentiation to generate pluripotent cells. These cells can be used to manufacture replacement tissues and organs to treat patients with chronic diseases such as diabetes, heart disease, or liver disease. Another business segment is the development of hydrogel-based technologies to enhance stem cell therapy. These technologies aim to accelerate tissue and organ regeneration and improve the effectiveness of stem cell therapies. AgeX Therapeutics also offers products and services in the field of diagnostics and insurance. The company has partnered with Juvenescence Ltd., a company in the field of aging research, to develop and introduce cancer diagnostic tests based on epigenetic markers. These tests aim to enable doctors to detect cancer at an early stage and initiate appropriate treatments. In addition, AgeX Therapeutics also offers services in the field of aging insurance. The company has partnered with Insilico Medicine, Inc. to develop machine learning technologies for identifying biological aging markers. These technologies aim to shape insurance rates based on individual biological age. AgeX Therapeutics has acquired a variety of patents and intellectual property, including the exclusive right to use GDF-11 technology for the treatment of aging processes. The company has also partnered with Lineage Cell Therapeutics, Inc. to advance the development of replacement tissues and organs based on pluripotent cells. In summary, AgeX Therapeutics' business model is based on the discovery and development of technologies for rejuvenation and regeneration of tissues and organs. The company focuses on the research of stem cells and their ability to regenerate tissues and organs. AgeX Therapeutics is divided into several business segments, each focusing on specific therapeutic approaches, and also offers products and services in the field of diagnostics and insurance. With its expertise in stem cells and regeneration, AgeX Therapeutics has the potential to play a leading role in the aging industry.

A(z) AgeX Therapeutics évente alkalommal oszt ki 0 USD összegű osztalékot.

A AgeX Therapeutics esetében jelenleg nem lehet kiszámítani a osztalékot, vagy a vállalat nem fizet osztalékot.

A(z) AgeX Therapeutics ISIN kódja: US00848H1086.

A AgeX Therapeutics WKN-je A2N8PC.

Az AgeX Therapeutics tőzsdei rövidítése SER.

Az elmúlt 12 hónapban a(z) AgeX Therapeutics osztalékot fizetett összegben. Ez körülbelül osztalékhozamnak felel meg. A következő 12 hóban a(z) AgeX Therapeutics várhatóan 0 USD összegű osztalékot fog fizetni.

A(z) AgeX Therapeutics jelenlegi osztalékhozama .

A(z) AgeX Therapeutics negyedévente fizet osztalékot. Az osztalékokat a következő hónapokban osztják ki: .

A AgeX Therapeutics az elmúlt 0 évben minden évben fizetett osztalékot.

A következő 12 hónapban 0 USD összegű osztalékra számítanak. Ez 0 % osztalékhozamnak felel meg.

A(z) AgeX Therapeutics a(z) 'Egészség' szektorhoz van besorolva.

Az utolsó, AgeX Therapeutics által 2024. 10. 01.-án/én fizetett 0 USD összegű osztalék megszerzéséhez a részvénynek az ex-nap előtti 2024. 10. 01.-nál kellett lennie a portfóliódban.

Az utolsó osztalék kifizetése 2024. 10. 01. időpontban történt.

2023 évben a AgeX Therapeutics 0 USD összegű osztalékot fizetett ki.

Az AgeX Therapeutics osztalékait USD fizeti ki.